Literature DB >> 11985515

Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs.

G Strauss1, W Osen, K-M Debatin.   

Abstract

Immunosuppressive drugs (ISD) are used for the prevention and treatment of graft rejection, graft-versus-host-disease (GVHD) and autoimmune disorders. The precise mechanisms by which ISD interfere with T cell activation and effector function or delete antigen-specific T cells are defined only partially. We analysed commonly used ISD such as dexamethasone (DEX), mycophenolic acid (MPA), FK506, cyclosporin A (CsA), rapamycin (RAP), methotrexate (MTX) and cyclophosphamide (CP) for apoptosis-induction and modulation of activation and effector function in human peripheral T cells, cytotoxic T cell lines (CTL) and Jurkat T cells. Of all drugs tested only CP and MTX prevented antigen-specific proliferation of T cells and decreased cytotoxicity of alloantigen specific CTL lines by direct induction of apoptosis. MTX and CP also slightly increased activation-induced cell death (AICD) and CD95-sensitivity. In contrast, all other drugs tested did not induce T cell apoptosis, increase CD95-sensitivity or AICD. CsA and FK506 even prevented AICD by down-modulation of CD95L. DEX, MPA, CsA, FK506 and RAP inhibited activation of naive T cells, but were not able to block proliferation of activated T cells nor decrease cytotoxic capacity of CTL lines. These results show that ISD can be classified according to their action on apoptosis-induction and inhibition of proliferation and would favour a rational combination therapy to delete existing reactive T cells and prevent further T cell activation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11985515      PMCID: PMC1906394          DOI: 10.1046/j.1365-2249.2002.01777.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  55 in total

1.  Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance.

Authors:  Y Li; X C Li; X X Zheng; A D Wells; L A Turka; T B Strom
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

Review 2.  The mechanism of action of cyclosporin A and FK506.

Authors:  S Ho; N Clipstone; L Timmermann; J Northrop; I Graef; D Fiorentino; J Nourse; G R Crabtree
Journal:  Clin Immunol Immunopathol       Date:  1996-09

3.  Activation-induced cell death in murine T cell hybridomas. Differential regulation of Fas (CD95) versus Fas ligand expression by cyclosporin A and FK506.

Authors:  T Brunner; N J Yoo; D LaFace; C F Ware; D R Green
Journal:  Int Immunol       Date:  1996-07       Impact factor: 4.823

4.  Release of preformed Fas ligand in soluble form is the major factor for activation-induced death of Jurkat T cells.

Authors:  M J Martínez-Lorenzo; M A Alava; A Anel; A Piñeiro; J Naval
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

5.  Regulation of the human interleukin-2 gene by the alpha and beta isoforms of the glucocorticoid receptor.

Authors:  C M Bamberger; T Else; A M Bamberger; F U Beil; H M Schulte
Journal:  Mol Cell Endocrinol       Date:  1997-12-31       Impact factor: 4.102

6.  Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.

Authors:  M Müller; S Strand; H Hug; E M Heinemann; H Walczak; W J Hofmann; W Stremmel; P H Krammer; P R Galle
Journal:  J Clin Invest       Date:  1997-02-01       Impact factor: 14.808

7.  Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens.

Authors:  J Dantal; M Hourmant; D Cantarovich; M Giral; G Blancho; B Dreno; J P Soulillou
Journal:  Lancet       Date:  1998-02-28       Impact factor: 79.321

8.  Inhibition of CTL induction by rapamycin: IL-2 rescues granzyme B and perforin expression but only partially restores cytotoxic activity.

Authors:  A P Makrigiannis; D W Hoskin
Journal:  J Immunol       Date:  1997-11-15       Impact factor: 5.422

9.  Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells.

Authors:  L Genestier; R Paillot; S Fournel; C Ferraro; P Miossec; J P Revillard
Journal:  J Clin Invest       Date:  1998-07-15       Impact factor: 14.808

10.  Spontaneous and glucocorticoid-induced apoptosis in human mature T lymphocytes.

Authors:  M Brunetti; N Martelli; A Colasante; M Piantelli; P Musiani; F B Aiello
Journal:  Blood       Date:  1995-12-01       Impact factor: 22.113

View more
  44 in total

1.  Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS).

Authors:  David T Teachey; Dana A Obzut; Kelly Axsom; John K Choi; Kelly C Goldsmith; Junior Hall; Jessica Hulitt; Catherine S Manno; John M Maris; Nicholas Rhodin; Kathleen E Sullivan; Valerie I Brown; Stephan A Grupp
Journal:  Blood       Date:  2006-06-06       Impact factor: 22.113

Review 2.  Harnessing programmed cell death as a therapeutic strategy in rheumatic diseases.

Authors:  Madhu Ramaswamy; Min Deng; Richard M Siegel
Journal:  Nat Rev Rheumatol       Date:  2011-02-01       Impact factor: 20.543

3.  Cortisol and epinephrine control opposing circadian rhythms in T cell subsets.

Authors:  Stoyan Dimitrov; Christian Benedict; Dennis Heutling; Jürgen Westermann; Jan Born; Tanja Lange
Journal:  Blood       Date:  2009-03-17       Impact factor: 22.113

4.  Anti-inflammatory effects of water extract from bell pepper (Capsicum annuum L. var. grossum) leaves in vitro.

Authors:  Mai Hazekawa; Yuko Hideshima; Kazuhiko Ono; Takuya Nishinakagawa; Tomoyo Kawakubo-Yasukochi; Tomoka Takatani-Nakase; Manabu Nakashima
Journal:  Exp Ther Med       Date:  2017-09-05       Impact factor: 2.447

5.  Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide.

Authors:  Ashley T Munchel; Yvette L Kasamon; Ephraim J Fuchs
Journal:  Best Pract Res Clin Haematol       Date:  2011-07-13       Impact factor: 3.020

6.  Pivotal role of dihydrofolate reductase knockdown in the anticancer activity of 2-hydroxyoleic acid.

Authors:  Victoria Lladó; Silvia Terés; Mónica Higuera; Rafael Alvarez; Maria Antònia Noguera-Salva; John E Halver; Pablo V Escribá; Xavier Busquets
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-03       Impact factor: 11.205

Review 7.  Optimal Management of Autoimmune Lymphoproliferative Syndrome in Children.

Authors:  Lindsey A George; David T Teachey
Journal:  Paediatr Drugs       Date:  2016-08       Impact factor: 3.022

8.  Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome.

Authors:  Yvette L Kasamon; Leo Luznik; Mary S Leffell; Jeanne Kowalski; Hua-Ling Tsai; Javier Bolaños-Meade; Lawrence E Morris; Pamela A Crilley; Paul V O'Donnell; Nancy Rossiter; Carol Ann Huff; Robert A Brodsky; William H Matsui; Lode J Swinnen; Ivan Borrello; Jonathan D Powell; Richard F Ambinder; Richard J Jones; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2010-01-18       Impact factor: 5.742

9.  Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help.

Authors:  S Heidt; D L Roelen; C Eijsink; M Eikmans; C van Kooten; F H J Claas; A Mulder
Journal:  Clin Exp Immunol       Date:  2009-11-18       Impact factor: 4.330

Review 10.  Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation.

Authors:  Leo Luznik; Paul V O'Donnell; Ephraim J Fuchs
Journal:  Semin Oncol       Date:  2012-12       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.